Introduction
Tardive dyskinesia (TD) is characterized by involuntary movements predominantly in the orofacial region and develops in approximately 20% of patients (5% cumulative annual incidence) during long-term treatment with typical antipsychotics. 1, 2 Several clinical variables such as aging, duration of antipsychotic treatment and female gender are associated with an increased propensity to develop TD, but their precise role in the pathophysiology of TD remains uncertain.
tially irreversible clinical course constitute an important limitation for treatment with typical antipsychotics. The identification of factors contributing to development of TD would be of considerable clinical interest for individualized treatment with antipsychotics and to further our understanding of the mechanism of action of antipsychotic agents.
As a conceptual framework, the variability in any drug effect, including side effects such as TD, can be partitioned into pharmacokinetic and pharmacodynamic components. [4] [5] [6] The term pharmacokinetics describes the 'drug concentration vs time' relationships in an organism by mathematical formulations of drug absorption from the site of administration, distribution and elimination by metabolism and/or excretion. 5 The pharmacodynamics explains the 'drug concentration vs response' relationships and the related biological covariates (eg receptors, second messenger systems). 5 Although TD may be observed in the absence of prior drug exposure in some cases, recent molecular investigations, animal models and family studies indicate that genetic factors importantly contribute to person-toperson variability in the risk for TD. [7] [8] [9] [10] [11] [12] [13] [14] The genetic variations in antipsychotic pharmacodynamics (eg polymorphisms of the dopamine D3 receptor) in relation to TD were reviewed elsewhere. [12] [13] [14] Most typical antipsychotics are in part metabolised by the genetically polymorphic cytochrome P450 2D6 (CYP2D6). [15] [16] [17] Approximately 7% of Caucasian populations are poor metabolizers (PMs) of CYP2D6 substrates, whereas the rest are extensive metabolizers (EMs). [18] [19] [20] CYP2D6 activity also displays marked interethnic differences among many populations. [19] [20] [21] Hence, genetic variation in CYP2D6 expression has been previously assessed as a potential pharmacokinetic risk factor for antipsychotic-related movement disorders including TD, in several studies. [22] [23] [24] [25] [26] [27] [28] Collectively, these pharmacogenetic investigations suggest an increased probability of developing TD and acute dystonia in PMs or in heterozygous EMs carrying one nonfunctional CYP2D6 allele.
The extent of metabolism of a drug by a given CYP is determined by both the affinity of the substrate-enzyme complex and the relative abundance of the particular CYP protein in relation to the total CYP content in the liver. Although CYP2D6 is important for the metabolism of typical antipsychotics, it accounts for only 2% of the total CYP content in the human liver. 29 Consequently, CYP2D6 is considered as a 'high affinity-low capacity' metabolic clearance pathway. 30 Consistent with this, the contribution of CYP2D6 to disposition of antipsychotics and other substrates is comparatively reduced during multiple [30] [31] [32] [33] [34] vs single-dose 31,35 drug administration. A considerable overlap in the distribution of antipsychotic serum concentration between EMs and PMs of CYP2D6 was also noted during chronic treatment. 33 Therefore, it is likely that metabolism by pathways other than CYP2D6 may also contribute to disposition of typical antipsychotics, especially under steady-state conditions during multiple-dose treatment.
The plasma concentration of most typical antipsychotics is significantly reduced by smoking, [36] [37] [38] [39] [40] [41] an established inducer of CYP1A2. 42 Conversely, the cessation of smoking was reported to increase chlorpromazine plasma concentration and adverse effects. 37 It is clinically well-established that more than 80% of patients with schizophrenia are smokers 43, 44 (compared with a 25% prevalence in the general population) 45 and thus, are likely to have an increased CYP1A2 activity and CYP1A2-dependent disposition of typical antipsychotics. Also, the amount of CYP1A2 protein in the human liver (12% of the total CYP content), on average, is approximately six-fold greater than that for CYP2D6. 29 The latter observation indicates that CYP1A2 may gain further importance in antipsychotic metabolism following CYP2D6 saturation at high substrate concentrations during long-term treatment. As such, CYP1A2 may be considered a 'low affinity-higher capacity' metabolic clearance pathway for typical anti-
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psychotics. In addition, fluvoxamine, a potent inhibitor of CYP1A2, [46] [47] [48] [49] increases the plasma concentration of typical antipsychotics (eg haloperidol), 50 further suggesting the involvement of CYP1A2 in antipsychotic metabolism. It should be noted that fluvoxamine can also inhibit other CYP enzymes (eg CYP2D6); 47 however, the in vitro inhibitory potency of fluvoxamine for CYP1A2 (K i = 0.24 M) 51 is approximately one order of magnitude greater than CYP2D6 (K i = 16.6 M) 52 and CYP3A4 (K i = 10.2 M). 52 Taken together, and considering the strong epidemiological association between smoking and schizophrenia, CYP1A2 can be viewed as another CYP (in addition to CYP2D6) which may contribute to disposition of typical antipsychotics in patients with schizophrenia during long-term treatment.
CYP1A2 activity exhibits at least 10-fold variability in vivo, which is under significant genetic control (h 1 = 0.83, using 3-methylxanthine formation from theophylline). [53] [54] [55] A recent study in a sample of 236 healthy Caucasian volunteers (185 nonsmokers and 51 smokers) identified a single nucleotide polymorphism (C→A) in intron 1 of the CYP1A2 gene at position 734 downstream from the transcription initiation site (allelic variants A and C). 56 In that sample, 56 46% were homozygous for the variant A, 44% were heterozygous, and 10% were homozygous for the variant C. The smokers with the C/C genotype had, on average, 40% lower CYP1A2 activity as measured by a plasma caffeine metabolic ratio [1,7- dimethylxanthine]/[caffeine], in comparison with those homozygous for the variant A. 56 In contrast, the (C→A) genetic polymorphism in CYP1A2 did not importantly contribute to variability in CYP1A2 activity in nonsmokers. 56 The aim of this study was to assess the clinical importance of the (C→A) genetic polymorphism in the CYP1A2 gene, in relation to risk for TD in patients with schizophrenia who were previously treated with typical antipsychotics.
Material and methods

Subjects
Subjects were patients with a DSM-IIIR diagnosis of schizophrenia who participated in an earlier study (n = 112). 13 From the earlier clinical sample, 13 16 documented non-smoking patients were excluded, as the (C→A) polymorphism in CYP1A2 does not influence CYP1A2 activity in nonsmokers. 56 In addition, PCR amplification was not successful for some samples or sufficient stock of DNA was not available from 11 patients, which yielded a total sample of 85 patients in the present study. Patients were recruited from three independent research clinics: the Case Western Reserve University in Cleveland (HY Meltzer, n = 51); the Hillside Hospital in Long Island (JA Lieberman, n = 22); and the University of California in Irvine (SG Potkin, n = 12). A written and informed consent was obtained from each patient.
The demographic attributes of the patients from each of the three clinical sites are presented in Table 1 . All patients were either treatment-refractory or intolerant to typical antipsychotics. Although a detailed antipsychotic treatment history was not available for the patients, it was established that all had been treated with typical antipsychotics from at least two chemical classes for a minimum of 1 year. Further, patients had received at least three periods of treatment with typical antipsychotics in the preceding 5 years at doses equivalent to or greater than 1000 mg day −1 of chlorpromazine for a period of at least 6 weeks, each without significant symptomatic relief. None of the patients were previously treated with atypical antipsychotics. The average duration of illness was 12.5 years (SD = 8.4). In terms of ethnicity, 74% of the patients were Caucasian, 26% were African-American. The Abnormal Involuntary Movement Scale (AIMS) was used to assess TD severity following a wash-out period of 2-4 weeks for typical antipsychotics. The wash-out period facilitates the clinical detection of TD, as explained in our previous study. 13 All three clinicians (HYM, JAL, SGP) had extensive experience in assessing TD severity, and exchange visits across the three clinical sites were arranged to ensure the consistency of administration of the AIMS.
Genotyping
Venous blood samples were collected from each patient and were analyzed at the Section of Neurogenetics, Centre for Addiction and Mental Health in Toronto. Genomic DNA was extracted from whole blood using a non-enzymatic, high-salt procedure. 57 A polymerase chain reaction (PCR) was performed in order to amplify the desired polymorphic portion of the CYP1A2 gene. 56 A 370-bp segment containing the (C→A) nucleotide substitution in intron 1 of the CYP1A2 gene was amplified by PCR using the following primers: 5Ј-CTA CTC CAG CCC CAG AAG TG-3Ј and 5Ј GAA GGG AAC AGA CTG GGA CA-3Ј. Amplification reactions were performed in a total volume of 25 l and each reaction contained 200 ng of genomic DNA, 0.16 mM of each dNTP (dATP, dTTP, dGTP, dCTP), 1× reaction buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl, 0.001% gelatin), 1.5 mM MgCl 2 , 1 unit of Taq polymerase and 0.8 M of each primer. Template genomic DNA was denatured at 99°C for 3 min before adding the reaction mixture. Subsequently, 30 cycles were performed, each consisting of 94°C for 60 s, 57°C for 60 s, and 72°C for 60 s. PCR products were digested overnight at 37°C with 1 unit of Bsp120I restriction endonuclease: allele A yielded an undigested single 370-bp band, while the allele C was represented by a 130-bp and a 240-bp band. These products were subjected to electrophoresis in a 2.5% agarose gel and visualized using ethidium bromide.
Statistical methods
The statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS), version 9.0. Analysis of Covariance (ANCOVA) was used to compare the mean AIMS scores for each of the genotypic classes, in a method similar to that of Basile and colleagues. 13 The ANCOVA statistic allowed the incorporation of several covariates into the statistical model (ethnicity, sex, age). When P Ͻ 0.05 was obtained in the ANCOVA, post-hoc Student-Newman-Keuls multiple comparisons were made to determine the categories that differed significantly. The demographics of our sample were statistically analyzed in order to determine any effects of sex and ethnicity that may have confounded the ANCOVA statistic. The assumptions of the ANCOVA statistic were tested in order to determine the appropriateness of our sample. The assumption of equal variance among each genotypic class was tested using the Levene Test for homogeneity of variances. The assumption of categorical groups with normally distributed values was tested for each genotypic panel using Kolmogorov-Smirnov Z tests. A chi-square test was used in order to test whether the distribution of genotypes was in accordance with the HardyWeinberg equilibrium. Power calculations were perfor-med based on mean AIMS scores and sample sizes, with alpha set to 0.05. P-values that were Bonferroni corrected for five multiple tests are also presented.
Results
There was a predominance of Caucasian and male patients in all three clinical samples (Table 1) . However, no statistically significant differences were found in the distribution of sex or ethnicity among the samples from the three different clinical sites. There was a significant difference observed between the mean age of the patients across the three clinical sites (F[2,82] = 5.04, P = 0.009) and using a StudentNewman-Keuls test, the mean ages of the Meltzer and Lieberman samples were significantly lower than that of the Potkin sample ( Table 1 ). The samples were combined into one group, producing a total of 85 patients. The allele frequencies (C = 0.38; A = 0.62) in this sample were similar to those previously reported by Sachse and coworkers. 56 Genotype frequencies for the CYP1A2 Bsp120I (C→A) polymorphism did not differ among patients from different clinical sites or between males and females. In addition, genotype frequencies did not differ significantly between Caucasians and AfricanAmericans ( 2 = 3.3, df = 2, P = 0.19), however, there was a trend for African-Americans to have a higher occurrence of the C allele (C = 0.48; A = 0.52) than did Caucasians (C = 0.34; A = 0.66). Also, mean age did not differ significantly between the patients grouped according to genotype (F[2,82] = 0.98, P = 0.38). When testing for Hardy-Weinberg equilibrium between the alleles of this polymorphism, sample genotype frequencies did not deviate significantly from the frequencies expected under random mating conditions ( 2 = 2.96, df = 2, P = 0.23).
It was found that the Bsp120I (C→A) polymorphism in the CYP1A2 gene was significantly associated with typical antipsychotic induced TD (F[2,82] = 7.41, P = 0.0007), with a statistical power of 0.69 and an r 2 value of 0.31. A post-hoc Student-Newman-Keuls test revealed higher mean AIMS scores in patients homozygous for the C allele of the CYP1A2 gene (mean AIMS of 17.8 ± 9.8 SD) when compared to heterozygous patients (mean AIMS of 6.6 ± 8.6 SD) and patients homozygous for the A allele (mean AIMS of 5.2 ± 7.9 SD). The mean AIMS score in patients with the (C/C) genotype (associated with reduced CYP1A2 inducibility) was 2.7-and 3.4-fold greater than those with the (A/C) or (A/A) genotype, respectively ( Figure  1 ). All the assumptions of the ANCOVA, namely normally distributed genotypic categories with equal variances across all groups, were evaluated. The Levene Test for homogeneity of variance revealed no significant differences (Levene statistic = 0.98, df 1 = 2, df 2 = 82, P = 0.379), and as such, this assumption of the ANCOVA model was fulfilled. Deviation from normality was noted in the distribution of data within the A/A and the A/C genotypes (Kolmogorov-Smirnov Z = 1.73, P = 0.005; Z = 1.3, P = 0.07, respectively). However, a nonparametric alternative, the Kruskal-Wallis In order to test for effects of ethnic stratification, we conducted an analysis that separated Caucasians and African-Americans. In both the Caucasian (n = 63) and the African-American (n = 22) groups, patients homozygous for the CYP1A2 C-allele displayed higher AIMS scores, but this was statistically significant in the Caucasian sample only (n = 63, F[2,60] = 5.96, P = 0.0004) (Figure 2a) . A similar trend was also observed in the African-American group, but this did not reach significance at the 5% level due to limited sample size (Figure 2b) .
The information on smoking status was available in only 44 out of 85 patients in the combined sample. However, an overwhelming majority of our sample (Ͼ80%, n = 85) are expected to be chronic smokers, based on our past clinical experiences with the patients participating in the present study, and the previously well-documented high prevalence (Ͼ80-90%) of smoking in the general population of patients with schizophrenia. 43, 44 Moreover, a subanalysis in 44 patients who were documented to be chronic smokers also revealed that the patients homozygous for the CYP1A2 C-allele had a 5.4-and 4.7-fold higher mean AIMS score than those carrying the (A/C) or (A/A) genotype, respectively (F[2,41] = 3.69, P = 0.008) (Figure 3 ). This . Each box displays the median (black bar), and the 25th and the 75th quartiles (the lower and the upper edges of the box, respectively), and the extreme values in CYP1A2 genotypes. An extreme value refers to a data point with a value more than three box lengths from the upper or lower edge of the box. The box length is the interquartile range. The number of patients in each genotype is presented beneath each box. Results from an ANCOVA analysis of AIMS against genotype class; with age, sex and ethnicity incorporated as covariates, are presented below the plot. In the Caucasian group, patients with the C/C genotype had a significantly higher AIMS score (15.9 ± 9.7) (mean ± SD) than those with the A/C (4.9 ± 6.1) or the A/A (3.9 ± 6.3) genotype. In African-American patients, a similar but nonsignificant trend was observed among the (C/C) (20.3 ± 10.1), the (A/C) (12.4 ± 13.4) and the (A/A) (9.7 ± 11.7) genotype classes. 
Discussion
Understanding the genetic basis of person-to-person variability in drug efficacy and safety is a fundamental focus for pharmacogenetic research and for rational and individualized drug treatment in clinical psychiatry. [58] [59] [60] [61] Genetic and/or environmental variation in drug metabolism is a pivotal factor which contributes to marked variability in pharmacokinetics and therapeutic/adverse effects of psychotropic medications. 6, 16, 21, [62] [63] [64] Historically, the CYP2D6 genetic polymorphism has been the primary research focus in relation to hereditary pharmacokinetic risk factors for TD. [22] [23] [24] [25] [26] [27] [28] However, since CYP2D6 can be saturated at high substrate concentrations, 30 the relative contribution of alternative metabolic pathways (eg CYP1A2) is likely to gain increased importance during chronic treatment with high doses of antipsychotics, particularly among schizophrenia patients with a high prevalence of smoking. It has been known for a long time that smoking induces drug metabolism and CYP1A2 activity. 42, 62 At the same time, marked variability in the extent of CYP1A2 induction among smokers was also noted, 42 which was previously explained in part by the number of cigarettes smoked. 42 The func-tional CYP1A2 genetic polymorphism reported by Sachse and coworkers provides further insight into mechanisms of genetic contribution to variability in CYP1A2 inducibility, with important clinical ramifications for CYP1A2 substrates. 56 The results of the present study indicate that patients with the (C/C) genotype for CYP1A2 are at an increased risk to develop more severe TD, compared with those who are heterozygous or homozygous for the CYP1A2 A-allele. Sachse and coworkers 56 have previously shown that the (C/C) genotype confers low-inducibility for CYP1A2 in smokers. Hence, the observed association of the (C→A) CYP1A2 polymorphism with TD may in part be attributable to variations in CYP1A2-dependent antipsychotic disposition and plasma concentration among smokers with different CYP1A2 genotypes. In addition, since the CYP1A2 activity is lower in smokers with the (C/C) genotype, 56 a second theoretical mechanism could be the increased propensity to produce putative unidentified neurotoxic antipsychotic metabolite(s) in patients with the (C/C) genotype, by alternative disposition routes other than CYP1A2. The change in CYP1A2 activity by the (C→A) polymorphism may be due to its direct effect on CYP1A2 expression or alternatively, it can be in linkage disequilibrium with a nearby regulatory sequence that controls CYP1A2 expression. Recently, a (G→A) polymorphism was identified in the 5Ј-flanking region of the CYP1A2 gene at position −2964 from the transcription initiation site in Japanese subjects. 65 This (G→A) single nucleotide polymorphism was associated with a significant decrease in CYP1A2 activity, as measured by the caffeine 3-demethylation rate. 65 Further studies are warranted to test the clinical repercussions of this CYP1A2 (G→A) genetic polymorphism in relation to TD risk in Asians. It would also be of interest to determine the degree of linkage disequilibrium between the (G→A) genetic polymorphism reported by Nakajima et al 65 and the (C→A) genetic polymorphism reported by Sachse and colleagues. 56 Although the smoking status was confirmed in 44 patients in the sample, detailed information on the amount of smoking was unavailable. Previously, we have shown that the extent of exposure to tobacco smoke positively correlates with the CYP1A2 activity. 42, 66 In addition, smoking may also alter the risk for TD by a pharmacodynamic effect of nicotine. 67, 68 Therefore, interindividual differences in the amount of cigarette consumption in our sample might have biased our observations. Similarly, variability in antipsychotic dose and duration of exposure are other potential sources confounding in our study. The increased TD severity in patients with the (C/C) genotype for CYP1A2 may also be a result of type I error, due to population stratification bias, although we attempted to control for this by including ethnicity as a cofactor and by conducting an ethnically stratified analysis. For further discussion of these and other potential confounding factors in pharmacogenetic studies of TD, see Basile et al. 13 In conclusion, the results of the present study sugMolecular Psychiatry gest that the (C→A) genetic polymorphism in the CYP1A2 gene contributes to the risk for the development of TD in patients with schizophrenia who are treated with typical antipsychotics. This finding was more pronounced in patients who were documented smokers. This result may provide a mechanistic basis for rational dosing of typical antipsychotics in smokers. Further studies in independent samples are warranted to evaluate the applicability of our findings to the general patient population receiving antipsychotic medications. Approximately 30% of the variance in the TD phenotype in our sample was explained by the proposed ANCOVA model. It is likely that other factors, possibly genetic variation in the dopamine D3 receptor, [12] [13] [14] as well as other genes and additional environmental influences, may account for the remaining variability in the TD phenotype. The future development of statistical models to test gene-gene interactions (eg DRD3 and CYP1A2) may provide further insight into potential interplay between pharmacodynamic and pharmacokinetic factors contributing to pathophysiology of TD. Such genetic interaction hypotheses are currently being assessed by our group. 69, 70 
